公开(公告)号：US20230134160A1

公开(公告)日：2023-05-04

申请号：US15761777

申请日：2016-09-08

申请人： PFIZER INC.

发明人： Judy Kay GLYNN ,  Brian Xin CHEN ,  Daniel Patrick LACASSE

IPC分类号： A61K39/395 ,  C07K1/34 ,  A61K47/22 ,  A61K47/26 ,  A61K47/18 ,  C07K16/28

摘要： The invention relates to a method of preparing a protein formulation including a therapeutic protein, the method comprising the steps of: providing a solution comprising said protein; concentrating the protein in the solution by a first ultra-filtration step; diafiltering the solution with a diafiltration buffer including at least one first excipient, whereby a retentate is obtained comprising the protein and the first excipient; further concentrating the protein in the retentate by a second ultra-filtration step; and adding at least one final excipient, whereby the protein formulation with a desired protein concentration is obtained. According to the inven tion, the method further comprises, before the second ultra-filtration step, adding a second excipient to the retentate obtained from the diafiltration step. The invention is also directed to antibody formulations produced by the foregoing method.

公开(公告)号：US20230124938A1

公开(公告)日：2023-04-20

申请号：US18049052

申请日：2022-10-24

申请人： Pfizer Inc.

发明人： Gary Erik Aspnes ,  Scott W. Bagley ,  John M. Curto ,  Matthew S. Dowling ,  David Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David A. Griffith ,  Kim Huard ,  Gajendra Ingle ,  Wenhua Jiao ,  Chris Limberakis ,  Alan M. Mathiowetz ,  David W. Piotrowski ,  Roger B. Ruggeri

IPC分类号： C07D401/14 ,  A61K31/496 ,  A61K31/4545 ,  C07D487/04 ,  A61P3/00 ,  A61P15/10 ,  A61P17/06 ,  A61P9/10 ,  A61P19/06 ,  A61P25/28 ,  A61P25/30 ,  A61P43/00 ,  A61P1/16 ,  A61P25/02 ,  A61P3/04 ,  A61P19/02 ,  A61P3/10 ,  A61P13/12 ,  A61P25/18 ,  A61P1/00 ,  A61P15/00 ,  A61P25/16 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04

摘要： Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US11597770B2

公开(公告)日：2023-03-07

申请号：US17154588

申请日：2021-01-21

申请人： Pfizer Inc.

发明人： James Reasoner Apgar ,  Sheryl Rubio Bowley ,  Joanne Elizabeth-Ayriss Elwell ,  Laura Lin ,  Jatin Narula ,  Chuenlei Parng ,  Debra Denene Pittman ,  Swapnil Rakhe ,  Chihyi Vincent Yu

IPC分类号： C07K16/28 ,  A61K39/00

摘要： The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.

公开(公告)号：US11578428B2

公开(公告)日：2023-02-14

申请号：US16836986

申请日：2020-04-01

申请人： Pfizer Inc.

发明人： William James Jonathan Finlay ,  Lioudmila Tchistiakova ,  Eric M. Bennett

IPC分类号： C40B50/06 ,  C07K16/00 ,  C07K16/18 ,  C07K16/40 ,  C40B40/10

摘要： Disclosed herein are humanized antibodies in which human germline residues are introduces to the complementarity determining regions (CDRs) of a non-human donor antibody. Also described herein are libraries of antibody variable domains (e.g., phage-display libraries) and methods for screening for humanized antibodies.

公开(公告)号：US20230045419A1

公开(公告)日：2023-02-09

申请号：US17782478

申请日：2020-12-07

申请人： Pfizer Inc.

发明人： Gary E. Aspnes ,  Scott W. Bagley ,  Wesley Dewitt Clark ,  John M. Curto ,  David James Edmonds ,  Mark E. Flanagan ,  Kentaro Futatsugi ,  David Andrew Griffith ,  Kim Huard ,  Yajing Lian ,  Chris Limberakis ,  Allyn T. Londregan ,  Alan M. Mathiowetz ,  David Walter Piotrowski ,  Roger B. Ruggeri

IPC分类号： C07D405/14

摘要： The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt for example, a hydrate (e.g. a monohydrate) crystalline form (e.g. Form 2 or Form 3) or an amorphous form; as well as pharmaceutical compositions, and the uses thereof in treating diseases, conditions or disorders modulated by GLP-1R in a mammal, such as a human.

公开(公告)号：US20230043985A1

公开(公告)日：2023-02-09

申请号：US17786695

申请日：2020-12-15

申请人： Pfizer Inc.

发明人： Meng LI ,  Kai-Hsin LIAO ,  Shinji YAMAZAKI

IPC分类号： A61K31/519 ,  A61K31/337 ,  A61K39/395 ,  A61K9/20 ,  A61P35/04 ,  A61P11/00

摘要： A method of treating cancers, including pancreatic cancer, endometrial cancer, non-small cell lung cancer (NSCLC), endometrial cancer, cervical cancer, bladder cancer, head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, esophageal cancer, and other cancers, the method comprising once-daily administration, to a patient in need thereof, of a therapeutically effective amount of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroiso quinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl) cyclopentane-1,2-diol having the structure: Formula I or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230041456A1

公开(公告)日：2023-02-09

申请号：US17843616

申请日：2022-06-17

申请人： Pfizer Inc.

发明人： Surabhi SRIVATSA SRINIVASAN ,  Niranjana NAGARAJAN ,  Siler PANOWSKI ,  Yoon PARK ,  Tao SAI ,  Barbra SASU ,  Thomas VAN BLARCOM ,  Mathilde DUSSEAUX ,  Roman GALETTO

IPC分类号： C07K16/28 ,  A61K39/00 ,  C07K14/725 ,  A61P35/02 ,  A61P35/04

摘要： The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).

公开(公告)号：US20230035617A1

公开(公告)日：2023-02-02

申请号：US17755573

申请日：2020-11-10

申请人： Pfizer Inc.

发明人： Thomas Joseph Crowley ,  Robert Lee Dufield ,  Jennifer Juneau

IPC分类号： A61K39/395 ,  C07K16/38 ,  A61K47/22 ,  A61K47/12 ,  A61K47/26 ,  A61P7/04

摘要： The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by an aqueous formulation of an anti-Tissue Factor Pathway Inhibitor (TFPI) antibody.

公开(公告)号：US11566006B2

公开(公告)日：2023-01-31

申请号：US17180296

申请日：2021-02-19

申请人： Pfizer Inc.

发明人： Elaine Greer ,  Stephen Anderson ,  Mark Maloney ,  Shu Yu ,  Ekaterina Albert ,  Emily Rigsbee

IPC分类号： C07D233/88 ,  A61K31/40

摘要： The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

公开(公告)号：US11559538B2

公开(公告)日：2023-01-24

申请号：US17082102

申请日：2020-10-28

申请人： Pfizer Inc.

发明人： Joseph Walter Strohbach ,  Tsutomu Akama ,  David Clive Blakemore ,  Robert Toms Jacobs ,  Peter Jones ,  David Christopher Limburg ,  Martins Sunday Oderinde ,  Matthew Alexander Perry ,  Jacob John Plattner ,  Rubben Federico Torella ,  Yasheen Zhou ,  Thean Yeow Yeoh

IPC分类号： C07F5/02 ,  A61K31/69 ,  A61K31/519

摘要： The present invention relates to boron containing compounds of Formula (IA): that inhibit phosphodiesterase 4 (PDE4). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating diseases, conditions, or disorders ameliorated by inhibition of PDE4.